
FDA Approves Giredestrant Plus Everolimus for ESR1-Mutated Breast Cancer
Giredestrant (Wilserdly) plus everolimus nearly doubled median PFS vs standard endocrine therapy plus everolimus in ESR1-mutated disease in evERA.
The FDA has approved giredestrant (Wilserdly), an oral estrogen receptor antagonist, in combination with everolimus for adults with estrogen receptor (ER)–positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer, as detected by an FDA-authorized test, whose disease recurred during or after endocrine-based adjuvant therapy or progressed on at least 1 endocrine-based regimen in the metastatic setting.1
The November 16, 2026, approval was based on the phase 3 evERA Breast Cancer trial, in which the all-oral combination reduced the risk of progression or death by 62% in patients with ESR1 mutations vs physician's choice of endocrine therapy plus everolimus.1,2
The FDA also approved the FoundationOne Liquid CDx assay as a companion diagnostic to identify patients with ESR1 mutations.1 Overall survival (OS) data were immature at the time of the progression-free survival (PFS) analysis.1
What did the evERA trial evaluate?
The randomized, open-label, multicenter evERA trial (NCT05306340) enrolled 373 adults with ER-positive, HER2-negative locally advanced or metastatic breast cancer, including 207 with ESR1-mutated tumors.1 Eligible patients had previously received a CDK4/6 inhibitor and endocrine therapy.3 Patients were randomly assigned 1:1 to giredestrant 30 mg once daily (n = 183) or physician's choice of endocrine therapy (exemestane, fulvestrant, or tamoxifen; n = 190), each with everolimus 10 mg once daily.1 Premenopausal women and men received a gonadotropin-releasing hormone agonist, except men who had undergone bilateral orchiectomy.1
The coprimary end points were investigator-assessed PFS in the intention-to-treat (ITT) and ESR1-mutated populations.3 Results were presented at the 2025 European Society for Medical Oncology Congress and published in The New England Journal of Medicine.2,4
What efficacy did giredestrant plus everolimus show?
In the ESR1-mutated population that forms the basis of the approval:
- Median PFS: 10 months (95% CI, 8.1-12.9) vs 5.5 months (95% CI, 3.8-5.6)
- PFS hazard ratio: 0.38 (95% CI, 0.27-0.54; P < .0001)
- Objective response rate: 27% (95% CI, 18-37) vs 14% (95% CI, 8-22)
In the ITT population, median PFS was 8.77 months with giredestrant plus everolimus vs 5.49 months with the comparator (HR, 0.56; 95% CI, 0.44-0.71; P < .0001).5 The approved indication is limited to patients with ESR1-mutated disease.1
"These results, including a near doubling of PFS in the ESR1 population, point to a highly effective new option for patients living with metastatic HR+ breast cancer," said Erica L. Mayer, MD, MPH, director of breast cancer clinical research at Dana-Farber Cancer Institute and principal investigator of evERA, at the time of the publication.4
What adverse events should nurses monitor for?
The most common adverse reactions, occurring in at least 20% of patients, were stomatitis, rash, fatigue, diarrhea, musculoskeletal pain, pneumonitis, and nausea.1 The most common laboratory abnormalities included decreased hemoglobin, lymphocytes, white blood cells, neutrophils, platelets, calcium, potassium, and sodium, and increased aspartate aminotransferase, alanine aminotransferase, and creatinine.1
Warnings and precautions for giredestrant include bradycardia and embryo-fetal toxicity.1 Because giredestrant is given with everolimus, the FDA directs clinicians to the everolimus prescribing information for that agent's dosing.1
Giredestrant is taken as 30 mg orally once daily, with or without food, until disease progression or unacceptable toxicity.1
How does giredestrant fit among oral SERDs?
In 2023, elacestrant became the first oral selective estrogen receptor degrader (SERD) approved for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer.6 ONN previously reported on
The FDA approved the application 4 weeks ahead of its goal date. The review was conducted under Project Orbis with Health Canada and the Israel Ministry of Health, and the applicant submitted an Assessment Aid.1 Separately, the FDA has granted priority review to giredestrant as adjuvant therapy for ER-positive, HER2-negative early breast cancer based on the phase 3 lidERA trial, with a target action date of November 30, 2026.8
What are the key takeaways for oncology nurses?
- ESR1 testing with an FDA-authorized assay, such as the FoundationOne Liquid CDx blood test, is required to identify eligible patients.1
- Stomatitis was among the most common adverse reactions, making oral care education a priority from the start of treatment.1
- New cough or shortness of breath warrants prompt assessment for pneumonitis.1
- Bradycardia is a labeled warning, so heart rate monitoring and patient education on dizziness or fatigue are relevant.1
- Counsel patients of reproductive potential on embryo-fetal toxicity and contraception.1
- OS data are immature; the approval rests on PFS, which is useful context for shared decision-making.1
References
- FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. US Food and Drug Administration. November 16, 2026. Accessed November 16, 2026.
https://www.fda.gov/drugs/cancer-approvals/fda-approves-giredestrant-combination-everolimus-er-positive-her2-negative-esr1-mutated-locally - Mayer E, et al. Giredestrant plus everolimus in advanced breast cancer. N Engl J Med. 2026;395(13):1285-1298. doi:10.1056/NEJMoa2602457
- FDA accepts new drug application for Genentech's giredestrant in ESR1-mutated, ER-positive advanced breast cancer. News release. Genentech. February 19, 2026. Accessed November 16, 2026.
https://www.businesswire.com/news/home/20260219248326/en/ - Novel treatment combination improves progression-free survival in most common form of metastatic breast cancer. News release. Dana-Farber Cancer Institute. October 1, 2026. Accessed November 16, 2026.
https://www.dana-farber.org/newsroom/news-releases/2026/novel-treatment-combination-improves-progression-free-survival-in-most-common-form-of-metastatic-breast-cancer - Inman S. Giredestrant/everolimus extends PFS for ER+, HER2– advanced breast cancer. OncLive. October 18, 2025. Accessed November 16, 2026.
https://www.onclive.com/view/giredestrant-everolimus-extends-pfs-for-er-her2--advanced-breast-cancer - Metastatic ER-positive, HER2-negative breast cancer: novel treatment combination improves progression-free survival. The ASCO Post. October 2025. Accessed November 16, 2026.
https://ascopost.com/news/october-2025/metastatic-er-positive-her2-negative-breast-cancer-novel-treatment-combination-improves-progression-free-survival/ - Fischer L. Oral SERDs: shifting the outpatient landscape of metastatic breast cancer? Oncology Nursing News. February 7, 2024. Accessed November 16, 2026.
https://www.oncnursingnews.com/view/oral-serds-shifting-the-outpatient-landscape-of-metastatic-breast-cancer- - Cortese T. FDA grants priority review to giredestrant in ER+/HER2– early breast cancer. CancerNetwork. June 3, 2026. Accessed November 16, 2026.
https://www.cancernetwork.com/view/fda-grants-priority-review-giredestrant-er-her2-early-breast-cancer
Related to this article








